Ergomed PLC (AIM:ERGO, ETR:2EM) said it made a good start to 2023, carrying on from the strong order book at the end of 2022.
Ahead of its AGM, Miroslav Reljanović, executive chairman, commented that, so far, the year has seen "solid overall growth" in revenues, reflecting its resilient services-based business model and the global strength of its offering.
“Investment has primarily been in our North American commercial capabilities, our global senior leadership presence, and also in technology as we continue to enhance our digital capabilities and the expansion of our service offering to our client base,” he added.
The pharma services specialist is debt free, with a strong balance sheet and unutilised facilities of up to £80mln to support continued expansion both organically and through acquisitions, Reljanović said.
“Based on our trading performance since the start of the year, the board anticipates financial results for the full year 2023 to be in line with market expectations.”